Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr

Holzner, Bernhard; Kemmler, Georg; Kopp, Martin; Nguyen-Van-Tam, Dominic P.; Sperner‐Unterweger, Barbara; Greil, Richard

doi:10.1111/j.1600-0609.2004.00233.x

Cited by 82 publications

(110 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Baseline scores for GHS/HRQoL were comparable with those reported from other studies of patients with CLL (GHS/HRQoL scores from previous studies have been reported as 64.5) [10,17]. The fact that HRQoL scores did not generally decline at progression may be due to the relatively short follow-up time for measuring HRQoL at progression, compared with the slow course of disease progression.…”

Section: Discussionsupporting

confidence: 81%

“…Scores for each domain are expressed on a 0-100 scale, with 0 being worst and 100 best for the functional and GHS/HRQoL domain, and 0 being best (fewer symptoms) and 100 being worst (more symptoms) for the individual symptom scores. This questionnaire has been used in several recent studies of patients with CLL [10,16,17]. The EORTC QLQ-CLL16 is intended as a supplementary module to the EORTC QLQ-C30.…”

Section: Patients and Study Designmentioning

confidence: 99%

See 1 more Smart Citation

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

et al. 2016

View full text Add to dashboard Cite

Offner (2016) Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL, Acta Oncologica, 55:9-10, 1115-1120, DOI: 10. Background: Patients diagnosed with chronic lymphocytic leukemia (CLL) are usually elderly and frequently have a number of comorbidities. Health-related quality of life (HRQoL) for these patients is of utmost importance and should be taken into consideration when assessing new treatment options. The combination of ofatumumab with chlorambucil has shown longer progression-free survival compared with chlorambucil alone. In this study, we aim to assess how this treatment combination affects patients' health-related quality of life and patient-reported symptoms. Material and methods:In this open-label phase III trial, patients with previously untreated CLL for whom fludarabine-based treatment was contra-indicated, were randomized 1:1 to receive oral chlorambucil (10 mg/m

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Patients and Study Designmentioning

confidence: 99%

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Moreover, recent data suggest that the quality of life in CLL patients is reduced compared with the normal population and only moderately increased by some of the current treatment options. [67][68][69][70] Therefore, further studies assessing the health-related quality of life in CLL are strongly encouraged.…”

Section: Treatment Endpointsmentioning

confidence: 99%

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Hallek

Cheson

Catovsky

et al. 2008

Blood

2,890

2,699

View full text Add to dashboard Cite

“…Nevertheless, evidence on QOL in this patient group is of importance as long-term survival rates increase and QOL has proven to be a useful clinical outcomemeasure and a major treatment goal in patients undergoing HCT. 4,5 Knowledge on QOL and its course over time may improve medical decision making and symptom management in this group of patients. This is especially true for long-term effects on QOL.…”

Section: Introductionmentioning

confidence: 99%

Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation

Pallua

Giesinger

Oberguggenberger

et al. 2010

Bone Marrow Transplant

View full text Add to dashboard Cite

Allogenic haematopoietic stem cell transplantation (HCT) has become an effective therapy in patients with various haematological malignancies. GvHD is known to be a major complication in this patient group and is assumed to have a major impact on patients' quality of life (QOL). Patients after BMT or transplantation of mobilized PBSCs were considered for enrolment in the study 6 months after transplantation. QOL and symptom burden were assessed using the EORTC QLQ-C30 and the QLQ-HDC29. Data from age-and sex-matched healthy controls were collected for comparison. In all, 100 patients (55.0% women; mean age 46.3 years) after allogeneic HCT were included in the study. In this patient group, we found a clinically relevant impact of GvHD on role functioning, global QOL, fatigue, dyspnoea, gastrointestinal side effects, worries/anxiety and skin problems. In comparison to healthy controls, various aspects of QOL were severely impaired. Our study revealed severe impairments of QOL in survivors of HCT, in particular in those suffering from GvHD. Taking into account, that the prevalence of GvHD might be higher in patients after PBSCT compared with patients after BMT, PBSCT is expected to lead to more severe impairments of QOL than BMT.

show abstract

Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr

Abstract: Patients suffering from CLL could have their QoL improved by more effective symptom management and psycho-oncological support. This could focus on specific symptoms such as fatigue and might have particular benefits for female patients with respect to their emotional and social well-being.

Cited by 82 publications

References 44 publications

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines

Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation

Contact Info

Product

Resources

About